Research ExplorerPublicationsRapid and strong antiviral activity of the non-nucleosidic N...

Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin.

Standard

Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. / Larrey, Dominique; Lohse, Ansgar W.; de Ledinghen, Victor; Trepo, Christian; Gerlach, Tilman; Zarski, Jean-Pierre; Tran, Albert; Mathurin, Philippe; Thimme, Robert; Arastéh, Keikawus; Trautwein, Christian; Cerny, Andreas; Dikopoulos, Nektarios; Schuchmann, Marcus; Heim, Markus H; Gerken, Guido; Stern, Jerry O; Wu, Katherine; Abdallah, Nasri; Girlich, Birgit; Scherer, Joseph; Berger, Frank; Marquis, Martin; Kukolj, George; Böcher, Wulf; Steffgen, Jürgen.

In: J HEPATOL, Vol. 57, No. 1, 1, 2012, p. 39-46.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Larrey, D, Lohse, AW, de Ledinghen, V, Trepo, C, Gerlach, T, Zarski, J-P, Tran, A, Mathurin, P, Thimme, R, Arastéh, K, Trautwein, C, Cerny, A, Dikopoulos, N, Schuchmann, M, Heim, MH, Gerken, G, Stern, JO, Wu, K, Abdallah, N, Girlich, B, Scherer, J, Berger, F, Marquis, M, Kukolj, G, Böcher, W & Steffgen, J 2012, 'Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin.', J HEPATOL, vol. 57, no. 1, 1, pp. 39-46. <http://www.ncbi.nlm.nih.gov/pubmed/22414766?dopt=Citation>

APA

Larrey, D., Lohse, A. W., de Ledinghen, V., Trepo, C., Gerlach, T., Zarski, J-P., Tran, A., Mathurin, P., Thimme, R., Arastéh, K., Trautwein, C., Cerny, A., Dikopoulos, N., Schuchmann, M., Heim, M. H., Gerken, G., Stern, J. O., Wu, K., Abdallah, N., ... Steffgen, J. (2012). Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J HEPATOL, 57(1), 39-46. [1]. http://www.ncbi.nlm.nih.gov/pubmed/22414766?dopt=Citation

Vancouver

Larrey D, Lohse AW, de Ledinghen V, Trepo C, Gerlach T, Zarski J-P et al. Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J HEPATOL. 2012;57(1):39-46. 1.

Bibtex

@article{aac840e6735b420d8b0a6fa74ae7eebf,
title = "Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin.",
abstract = "BI 207127 is a potent non-nucleoside hepatitis C virus (HCV) NS5B polymerase inhibitor in vitro.",
keywords = "Adult, Humans, Male, Aged, Female, Middle Aged, Adolescent, Young Adult, Treatment Outcome, Drug Therapy, Combination, Drug Resistance, Viral, Hepatitis C, Chronic/*drug therapy, Antiviral Agents/*administration & dosage/adverse effects/pharmacokinetics, Hepacivirus/*drug effects, Interferon-alpha/*administration & dosage/adverse effects/pharmacokinetics, Polyethylene Glycols/*administration & dosage/adverse effects/pharmacokinetics, Recombinant Proteins/administration & dosage/adverse effects/pharmacokinetics, Ribavirin/*administration & dosage/adverse effects/pharmacokinetics, Viral Nonstructural Proteins/*antagonists & inhibitors, Adult, Humans, Male, Aged, Female, Middle Aged, Adolescent, Young Adult, Treatment Outcome, Drug Therapy, Combination, Drug Resistance, Viral, Hepatitis C, Chronic/*drug therapy, Antiviral Agents/*administration & dosage/adverse effects/pharmacokinetics, Hepacivirus/*drug effects, Interferon-alpha/*administration & dosage/adverse effects/pharmacokinetics, Polyethylene Glycols/*administration & dosage/adverse effects/pharmacokinetics, Recombinant Proteins/administration & dosage/adverse effects/pharmacokinetics, Ribavirin/*administration & dosage/adverse effects/pharmacokinetics, Viral Nonstructural Proteins/*antagonists & inhibitors",
author = "Dominique Larrey and Lohse, {Ansgar W.} and {de Ledinghen}, Victor and Christian Trepo and Tilman Gerlach and Jean-Pierre Zarski and Albert Tran and Philippe Mathurin and Robert Thimme and Keikawus Arast{\'e}h and Christian Trautwein and Andreas Cerny and Nektarios Dikopoulos and Marcus Schuchmann and Heim, {Markus H} and Guido Gerken and Stern, {Jerry O} and Katherine Wu and Nasri Abdallah and Birgit Girlich and Joseph Scherer and Frank Berger and Martin Marquis and George Kukolj and Wulf B{\"o}cher and J{\"u}rgen Steffgen",
year = "2012",
language = "English",
volume = "57",
pages = "39--46",
journal = "J HEPATOL",
issn = "0168-8278",
publisher = "Elsevier",
number = "1",

}

RIS

TY - JOUR

T1 - Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin.

AU - Larrey, Dominique

AU - Lohse, Ansgar W.

AU - de Ledinghen, Victor

AU - Trepo, Christian

AU - Gerlach, Tilman

AU - Zarski, Jean-Pierre

AU - Tran, Albert

AU - Mathurin, Philippe

AU - Thimme, Robert

AU - Arastéh, Keikawus

AU - Trautwein, Christian

AU - Cerny, Andreas

AU - Dikopoulos, Nektarios

AU - Schuchmann, Marcus

AU - Heim, Markus H

AU - Gerken, Guido

AU - Stern, Jerry O

AU - Wu, Katherine

AU - Abdallah, Nasri

AU - Girlich, Birgit

AU - Scherer, Joseph

AU - Berger, Frank

AU - Marquis, Martin

AU - Kukolj, George

AU - Böcher, Wulf

AU - Steffgen, Jürgen

PY - 2012

Y1 - 2012

N2 - BI 207127 is a potent non-nucleoside hepatitis C virus (HCV) NS5B polymerase inhibitor in vitro.

AB - BI 207127 is a potent non-nucleoside hepatitis C virus (HCV) NS5B polymerase inhibitor in vitro.

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Adolescent

KW - Young Adult

KW - Treatment Outcome

KW - Drug Therapy, Combination

KW - Drug Resistance, Viral

KW - Hepatitis C, Chronic/drug therapy

KW - Antiviral Agents/administration & dosage/adverse effects/pharmacokinetics

KW - Hepacivirus/drug effects

KW - Interferon-alpha/administration & dosage/adverse effects/pharmacokinetics

KW - Polyethylene Glycols/administration & dosage/adverse effects/pharmacokinetics

KW - Recombinant Proteins/administration & dosage/adverse effects/pharmacokinetics

KW - Ribavirin/administration & dosage/adverse effects/pharmacokinetics

KW - Viral Nonstructural Proteins/antagonists & inhibitors

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Adolescent

KW - Young Adult

KW - Treatment Outcome

KW - Drug Therapy, Combination

KW - Drug Resistance, Viral

KW - Hepatitis C, Chronic/drug therapy

KW - Antiviral Agents/administration & dosage/adverse effects/pharmacokinetics

KW - Hepacivirus/drug effects

KW - Interferon-alpha/administration & dosage/adverse effects/pharmacokinetics

KW - Polyethylene Glycols/administration & dosage/adverse effects/pharmacokinetics

KW - Recombinant Proteins/administration & dosage/adverse effects/pharmacokinetics

KW - Ribavirin/administration & dosage/adverse effects/pharmacokinetics

KW - Viral Nonstructural Proteins/antagonists & inhibitors

M3 - SCORING: Journal article

VL - 57

SP - 39

EP - 46

JO - J HEPATOL

JF - J HEPATOL

SN - 0168-8278

IS - 1

M1 - 1

ER -